AVANIR Pharmaceuticals Invites Investors to the Bank of America and the UBS Global Life Sciences Conference Webcasts

AVANIR Pharmaceuticals (AMEX:AVN) will be presenting at
Bank of America's 35th Annual Investment Conference on Thursday,
September 22, 2005 at 7:30 a.m. PT in San Francisco, and at the UBS
Global Life Sciences Conference on Thursday, September 29, 2005 at
9:00 a.m. ET in New York. AVANIR's President and Chief Executive
Officer, Eric K. Brandt, will be presenting at the conferences.
   The live webcasts of the presentations will be accessible through
AVANIR's corporate website at http://www.avanir.com. To access the
webcasts, log on to AVANIR's site fifteen minutes prior to the
presentation to register and download any necessary audio software.
Archived versions of the presentations will be available until October
30, 2005.
   AVANIR Pharmaceuticals is focused on developing and
commercializing novel therapeutic products for the treatment of
chronic diseases. AVANIR's product candidates address therapeutic
markets that include central nervous system and cardiovascular
disorders, inflammation, and infectious disease. AVANIR recently
submitted to the FDA the last reviewable unit of its "rolling" new
drug application for Neurodex(TM) for the treatment of pseudobulbar
affect. Additionally, AVANIR has initiated a Phase 3 clinical trial of
Neurodex(TM) for the treatment of diabetic neuropathic pain. AVANIR
has active collaborations with two international pharmaceutical
companies: Novartis International Pharmaceutical Ltd. for the
treatment of inflammatory disease and AstraZeneca UK Limited for the
treatment of cardiovascular disease. The Company's first
commercialized product, Abreva(R), is marketed in North America by
GlaxoSmithKline Consumer Healthcare and is the leading
over-the-counter product for the treatment of cold sores. Further
information about AVANIR can be found at www.avanir.com.

   The information contained in this press release, including any
forward-looking statements contained herein, should be reviewed in
conjunction with the company's most recent Annual Report on Form 10-K
and other publicly available information regarding the company. Copies
of such information are available from the company upon request. Such
publicly available information sets forth many risks and uncertainties
related to the company's business and technology. Forward-looking
statements often contain such words like "estimate," "anticipate,"
"believe," "plan" or "expect." The company disclaims any intent or
obligation to update these forward-looking statements. Final review
decisions made by the FDA and other regulatory agencies concerning
clinical trial results are unpredictable and outside the influence
and/or control of the company.